Knowledge Library
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation is G12C, which comprises nearly 15% of lung adenocarcinomas, 8% of colorectal carcinomas and 4% of pancreatic adenocarcinomas. AMG-510 from Amgen and MRTX849 from Mirati Therapeutics, both targeting the KRASG12C mutant, have shown encouraging results …Read More >
Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes
How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox
Outsourcing Drug Discovery and Development: Considerations For Emerging Biopharma Companies
Quantum Mechanics for Organic Chemists: An Experimentalist Approach
Magical Power of Quantum Mechanics EBook Would you like to predict organic reaction outcomes accurately? Design synthetic sequences with higher rate of success? Would you prefer to learn and rationalize organic chemistry in a data-driven manner? Quantum Mechanics (QM) tools for chemistry are evolving at a tremendously fast pace and have proven to be invaluable for …Read More >
Targeted Protein Degradation Platform
Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION & DEGRADATION In vitro Assays-Target ubiquitination Target degradation assay PK/PD Animal Disease Model Evaluation CHEMISTRY Specific virtual library design Compound synthesis Conjugation and all type of custom syntheses from milligram to kilogram scale Purification and analytical …Read More >
Antibody and Protein Preparation Services
Integrated Drug Discovery Platform for Antibody & Protein Preparation We are dedicated to offering an integrated and cost-effective services platform of polyclonal and monoclonal antibodies, including: Antigen design and preparation Anti-drug antibodies (ADA) Host cell protein (HCP) antibodies Surrogate antibodies Diagnostic antibodies Therapeutic antibodies Learn about our services platform for evaluating bispecific antibodies
One-stop DEL services from target to hit series – DELpro
WuXi AppTec provides a one-stop solution for DEL services from target to hit series. Our extended platform enables overall planning and management of protein production, DEL library production, affinity selection, data analysis, hit validation and structural biology for further optimization.
Open Access to DEL for data sharing – DELopen
DELopen platform is dedicated to the development and application of DEL technology in drug discovery. Free access to DEL, data sharing. DELopen encourages an open, community-based approach to data sharing and exploration of the capabilities of DEL technology. We envision that DELopen will help academia benefits from the efficiency of DEL and unlock the full …Read More >